Prostacyclin receptor agonist Selexipag in patients with pulmonary arterial hypertension and congenital heart disease

Trial Profile

Prostacyclin receptor agonist Selexipag in patients with pulmonary arterial hypertension and congenital heart disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Selexipag (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Acronyms SELECT trial
  • Most Recent Events

    • 20 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top